How have TRGNF shares performed in 2024?

Transgene's stock was trading at $1.62 at the beginning of the year. Since then, TRGNF stock has decreased by 19.8% and is now trading at $1.30. View the best growth stocks for 2024 here .

How do I buy shares of Transgene?

Shares of TRGNF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

OTCMKTS:TRGNF

Transgene (TRGNF) Stock Price, News & Analysis

→ Bill Clinton Backing Biden Replacement??? (From The Freeport Society) (Ad)

Free TRGNF Stock Alerts

$1.30

0.00 (0.00%)

(As of 05/31/2024 ET)

Compare

Today's Range: $1.30
▼
$1.30
50-Day Range: $1.30
▼
$1.62
52-Week Range: $1.30
▼
$1.30

Volume: N/A
Average Volume: 433 shs
Market Capitalization: N/A

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: N/A

Stock Analysis Chart

Get Transgene alerts:

Ad Timothy Sykes

Bill Gates is all about this tiny $2 stock

What does Bill Gates know about this tiny company that we don’t? From the outside, it looks like a worthless $2 stock…

>>Click here to discover why Bill Gates is all about this tiny $2 stock.

About Transgene Stock (OTCMKTS:TRGNF)

Transgene SA, a biotechnology company, focuses on designing and developing therapeutic vaccines and oncolytic viruses for the treatment of cancer in France. It involved in developing TG4050, a therapeutic vaccine that is in Phase I clinical trial for the treatment of ovarian cancer, and head and neck cancers; TG4001, a therapeutic vaccine, which is in Phase II clinical trial for the treatment of HPV-positive cancers; TG6002, an oncolytic virus that is in Phase I/IIa clinical trial for the treatment of gastrointestinal and colorectal cancers; and BT-001, an oncolytic virus, which is in Phase I/II clinical trial for the treatment of solid tumors. The company also develops TG1050, a therapeutic vaccine for the treatment of hepatitis B; TG6050 for the treatment of non-small cell lung cancer, and Pexa-Vec, an oncolytic virus for the treatment of solid tumors. It has strategic collaboration agreements with AstraZeneca, Merck KGaA, Pfizer, and NEC Corporation; licensing agreements with SillaJen, Ascend BioPharmaceutical, and Valneva; and agreements with Merck & Co, Sanofi, BioInvent, and Randox. Transgene SA was incorporated in 1979 and is headquartered in Illkirch-Graffenstaden, France. Transgene SA is a subsidiary of TSGH SAS.

TRGNF Stock Price History

30 days | 90 days | 365 days | Advanced Chart

TRGNF Stock News Headlines

No headlines for this company have been tracked by MarketBeat.com

Receive TRGNF Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Transgene and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange: OTCMKTS
Sector: Medical
Industry: Biotechnology
Sub-Industry: N/A
Current Symbol: OTCMKTS:TRGNF
CUSIP: N/A
CIK: N/A
Web: www.transgene.fr
Phone: (338) 827-9100
Fax: N/A
Employees: 141
Year Founded: N/A

Profitability

EPS (Most Recent Fiscal Year): N/A
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: N/A
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: N/A
Return on Assets: N/A

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: N/A
Quick Ratio: N/A

Sales & Book Value

Annual Sales: N/A
Price / Sales: N/A
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: N/A
Price / Book: N/A

Miscellaneous

Outstanding Shares: N/A
Free Float: N/A
Market Cap: N/A
Optionable: Not Optionable
Beta: N/A

Beginner's Guide to Pot Stock Investing

Click the link below and we'll send you MarketBeat's guide to pot stock investing and which pot companies show the most promise.

Get This Free Report

Key Executives

Dr. Alessandro Riva M.D. (Age 63)
CEO & Chairman of the Board
Comp: $71.79k
Ms. Lucie Larguier
Chief Financial Officer
Dr. Eric Quemeneur Ph.D. (Age 59)
Pharm.D., Executive VP & Chief Scientific Officer
Mr. John Felitti J.D. (Age 54)
LLM, VP, General Counsel & Corporate Secretary
Ms. Christelle Schwoerer
Chief Human Resources Officer
Dr. Maud Brandely-Talbot M.D. (Age 70)
Ph.D., VP of Medical Affairs & Chief Medical Officer
Mr. James Wentworth M.B.A.
Ph.D., VP & Chief Business Officer
Ms. Gaelle Stadtler (Age 40)
VP & Director of Human Resources
Kaidre Bendjama
Project Leader of Personalized Cancer Vaccines
Ms. Elisabetta Castelli Ph.D.
Director of Investor Relations

Key Competitors

View All Competitors

TRGNF Stock Analysis - Frequently Asked Questions

How have TRGNF shares performed in 2024?: Transgene's stock was trading at $1.62 at the beginning of the year. Since then, TRGNF stock has decreased by 19.8% and is now trading at $1.30.
View the best growth stocks for 2024 here.
How do I buy shares of Transgene?: Shares of TRGNF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (OTCMKTS:TRGNF) was last updated on 6/2/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial